A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome

Nephrology Dialysis Transplantation

Volumn 24, Issue 10, 2009, Pages 2960-2964

  Shimada, Michiko ^a   Johnson, Richard J ^a,b   May, William Stratford ^a   Lingegowda, Vijaykumar ^a   Sood, Puneet ^a   Nakagawa, Takahiko ^a,b   Van, Quoc C ^a   Dass, Bhagwan ^a   Ejaz, Abutaleb Ahsan ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Serum uric acid; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; CALCIUM PHOSPHATE; INTERCELLULAR ADHESION MOLECULE 1; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RASBURICASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR; URATE; URIC ACID;

ACUTE DISEASE; CHEMOSENSITIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GRANULOMATOUS INFLAMMATION; HUMAN; KIDNEY INJURY; PRIORITY JOURNAL; SHORT SURVEY; TUMOR LYSIS SYNDROME; UPREGULATION; URIC ACID BLOOD LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; CRYSTALLIZATION; HUMANS; TUMOR LYSIS SYNDROME; URIC ACID;

EID: 70349492441     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp330     Document Type: Short Survey

References (64)

1. Coiffier B, Altman A, Pui CH et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767-2778
2. Wössmann W, Schrappe M, Meyer U et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/ leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160-165
3. Seidemann K, Meyer U, Jansen P et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lym-phoma and B-ALL. Observations from the BFM-trials. Klin Padiatr 1998; 210: 279-284
4. Pumo V, Sciacca D, Malaguarnera M. Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol 2007; 64: 31-42
5. Hsu HH, Chan YL, Huang CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol 2004; 17: 50-56
6. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
7. Ponte B, Felipe C, Muriel A et al. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol Dial Transplant 2008; 23: 3859-3866
8. Montesinos P, Lorenzo I, Mart́in G et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93: 67-74
9. Hsu CY, Ordoñez JD, Chertow GM et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 74: 101-107
10. Boles JM, Dutel JL, Briere J et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapyofan acute lymphoblas-tic leukemia. Cancer 1984; 53: 2425-2429
11. Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 2003; 18: 664-669
12. Emmerson BT, Cross M, Osborne JM et al. Reaction of MDCK cells to crystals of monosodium urate monohydrate and uric acid. Kidney Int 1990; 37: 36-43
13. Kim YG, Huang XR, Suga S et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol Med 2000; 6: 837-848
14. Klinenberg JR, Kippen I, Bluestone R. Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron 1975; 14: 88-98
15. Farebrother DA, Pincott JR, Simmons HA et al. Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. J Pathol 1981; 135: 159-168
16. Kellermeyer RW, Naff GB. Chemical mediators of inflammation in acute gouty arthritis. Arthritis Rheum 1975; 18: 765-770
17. Terkeltaub R. Gout and mechanisms of crystal-induced inflammation. Curr Opin Rheumatol 1993; 5: 510-516
18. Simchowitz L, Atkinson JP, Spilberg I. Stimulation of the respiratory burst in human neutrophils by crystal phagocytosis. Arthritis Rheum 1982; 25: 181-188
19. Phelps P. Polymorphonuclear leukocyte motility in vitro II. Stimulatory effect of monosodium urate crystals and urate in solution; partial inhibition by colchicine and indomethacin. Arthritis Rheum 1969; 12: 189-196
20. Roberge CJ, de Médicis R, Dayer JM et al. Crystal-induced neutrophil activation: V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol 1994; 152: 5485-5494
21. Serhan CN, Lundberg U, Weissmann G et al. Formation of leukotrienes and hydroxy acids by human neutrophils and platelets exposed to monosodium urate. Prostaglandins 1984; 27: 563-581
22. Terkeltaub R, Zachariae C, Santoro D et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991; 34: 894-903
23. Liu R, O'Connell M, Johnson K et al. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulatedbymonosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000; 43: 1145-1155
24. di Giovine FS, Malawista SE, Thornton E et al. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991; 87: 1375-1381
25. Murakami Y, Akahoshi T, Hayashi I et al. Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovi-rally transfected prostaglandin D synthase. Arthritis Rheum 2003; 48: 2931-2941
26. Guerne PA, Terkeltaub R, Zuraw B et al. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32: 1443-1452
27. Chen CJ, Shi Y, Hearn A et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116: 2262-2271
28. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521
29. Webb R, Jeffries M, Sawalha AH. Uric acid directly promotes human T-cell activation. Am J Med Sci 2009; 337: 23-27
30. Behrens MD, Wagner WM, Krco CJ et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2008; 111: 1472-1479
31. Linas SL, Whittenburg D, Parsons PE et al. Ischemia increases neu-trophil retention and worsens acute renal failure: role of oxygen metabolites and ICAM 1. Kidney Int 1995; 48: 1584-1591
32. Temonen M, Mustonen J, Helin H et al. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. Clin Immunol Immunopathol 1996; 78: 47-55
33. Shigeoka AA, Holscher TD, King AJ et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J Immunol 2007; 178: 6252-6258
34. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17: 1503-1520
35. Ames BN, Cathcart R, Schwiers E et al. Uric acid provides an antioxi-dant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981; 78: 6858-6862
36. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
37. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-932
38. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59
39. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces en-dothelial dysfunction. Kidney Int 2005; 67: 739-1742
40. Kang DH, Park SK, Lee IK et al. Uric acid induced C-reactive protein (CRP) expression: implication on cell proliferation, and nitric oxide production in human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562
41. Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281-287
42. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897
43. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt sensitivity. Hypertension 2002; 40: 355-360
44. Zare F, Magnusson M, Bergström T et al. Uric acid, a nucleic acid degradation product, down-regulates dsRNA-triggered arthritis. J Leukoc Biol 2006; 79: 482-488
45. Han HJ, Lim MJ, Lee YJ et al. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol 2007; 292: F373-F381
46. Cirillo P, Gersch MS, Mu W et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 2009; 20: 545-553
47. Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/ nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596
48. Kang DH, Han L, Ouyang X et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005; 25: 425-433
49. Price KL, Sautin YY, Long DA et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006; 17: 1791-1795
50. Gersch C, Palii SP, Imaram W et al. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 2009; 28: 118-149
51. Gersch C, Palii SP, Kim KM et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008; 27: 967-978
52. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106
53. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997
54. Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropa-thy. J Am Soc Nephrol 2007; 18: 539-550
55. Sánchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyperuricemia induces severe cortical vasoconstriction and perpetuates glomerular hypertension in normal rats and in experimental chronic renal failure. Kidney Int 2005; 67: 237-247
56. Sánchez-Lozada LG, Tapia E, Avila-Casado C et al. Mild hyper-uricemia induces glomerular hypertension in normal rats. Am J Phys-iol Renal Physiol 2002; 283: F1105-F1110
57. Sánchez-Lozada LG, Tapia E, López-Molina R et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 2007; 292: F1238-F1244
58. Sánchez-Lozada LG, Soto V, Tapia E et al. Role of oxida-tive stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295: F1134-F1141
59. Roncal CA, Mu W, Croker B et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2007; 292: F116-F122
60. Nanji AA, Stewart DJ, Mikhael NZ. Hyperuricemia and hypoal-buminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 1986; 17: 274-276
61. Shimada M, Lingegowda V, Sood P et al. Uric acid is a Novel Risk Factor for Acute Kidney Injuryin High-Risk Cardiac SurgeryPatients. Abstract World Congress of Nephrology 2009; # 950819
62. Ejaz AA, Mu W, Kang DH et al. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol 2007; 2: 16-21
63. Mato AR, Riccio BE, Qin L et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma 2006; 47: 877-883
64. Montesinos P, Lorenzo I, Mart́in G et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93: 67-74